Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hynder M. Al-kuraishy a, Ali I. Al-Gareeb a, Safaa Qusti b, Eida M. Alshammari c, Francis O. Atanu d, Gaber El-Saber Batiha a,*,

a Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustaniriyia University, Baghdad, Iraq
b Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
c Department of Chemistry, College of Sciences, University of Ha'il, Ha'il, Saudi Arabia
d Department of Biochemistry, Faculty of Natural Sciences, Kogi State University, P.M.B. 1008 Anyigba, Nigeria

* Corresponding author.
E-mail addresses: Hayderm36@yahoo.com (H.M. Al-kuraishy), Dr.alialgareeb78@yahoo.com (A.I. Al-Gareeb), squsti@kau.edu.sa (S. Qusti), eida.alshammari@uoh.edu.sa (E.M. Alshammari), atanufo@gmail.com, atanu.fo@ksu.edu.ng (F.O. Atanu), dr_gaber_batiha@vetmed.dmu.edu.eg (G.E.-S. Batiha).

https://doi.org/10.1016/j.biopha.2021.112193

Received 24 June 2021; Received in revised form 6 September 2021; Accepted 10 September 2021
Available online 15 September 2021

© 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license.

ABSTRACT

In Covid-19, systemic disturbances may progress due to development of cytokine storm and dysregulation of and plasma osmolarity due to high release of pro-inflammatory cytokines and neuro-hormonal disorders. Arginine vasopressin (AVP) which is involve in the regulation of body osmotic system, body water content, blood pressure and plasma volume, that are highly disturbed in Covid-19 and linked with poor clinical outcomes. Therefore, this present study aimed to find the potential association between AVP serum level and inflammatory disorders in Covid-19. It has been observed by different recent studies that physiological response due to fever, pain, hypovolemia, dehydration, and psychological stress is characterized by activation release of AVP to counterbalance high blood viscosity in Covid-19 patients. In addition, activated immune cells mainly T and B lymphocytes and released pro-inflammatory cytokines stimulate discharge of stored AVP from immune cells, which in a vicious cycle trigger release of pro-inflammatory cytokines. Vasopressin receptor antagonists have antiviral and anti-inflammatory effects that may inhibit AVP-induced hyponatremia and release of pro-inflammatory cytokines in Covid-19. In conclusion, release of AVP from hypothalamus is augmented in Covid-19 due to stress, high pro-inflammatory cytokines, high circulating AngII and inhibition of GABAergic neurons. In turn, high AVP level leads to induction of hyponatremia, inflammatory disorders, and development of complications in Covid-19 by activation of NF-kB and NLRP3 inflammasome with release of pro-inflammatory cytokines. Therefore, AVP antagonists might be novel potential therapeutic modality in treating Covid-19 through mitigation of AVP-mediated inflammatory disorders and hyponatremia.

Keywords: Covid-19 Arginine vasopressin Hyponatremia

1. Background

From the beginning of coronavirus disease 2019 (Covid-19) pandemic there is a substantial worldwide impact on the health system due to high rate of hospitalization and high fatality rate especially in patients admitted in the intensive care unit [1]. Up to date, the total infected patients globally reach to more than 170 million with more than 3 million confirmed death cases in late May of 2021. Nonetheless, the ongoing and oncoming rise of infected cases is still alarming primarily with emerging of variant strains of this pandemic [2]. Covid-19 is caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped positive sense single strand RNA virus from Betacoronaviridae family, it has 79% similarity with SARS-CoV pandemic 2003 and about 40% with Middle East Respiratory Syndrome coronavirus (MERS-CoV) 2012. Most of SARS-CoV-2 variant strains have a high similarity with novel SARS-CoV-2 ranged from 81% to 96% [3].

The pathophysiological role of SARS-CoV-2 infection is mediated by direct viral toxicity, abnormal immune response, endothelial dysfunction, dysregulated renin-angiotensin system (RAS), and thrombo-inflammation that lead to pulmonary and extra-pulmonary manifestations [4]. The angiotensin converting enzyme 2 (ACE2) is regarded as the main receptor for entry of SARS-CoV-2 that is expressed in various
tissue principally in lung epithelial alveolar type II cells, endothelial cells, enterocytes and cardiomyocytes [5,6]. The pulmonary manifestations of SARS-CoV-2 infections are asymptomatic in 80% of infected cases however 15% of infected patients may develop pneumonitis and acute lung injury (ALI), while 5% of infected patients experience a critical Covid-19 due to progression of acute respiratory distress syndrome (ARDS) [7]. Moreover, systemic disturbances may progress due to development of cytokine storm and dysregulation of and plasma osmolarity due to high release of pro-inflammatory cytokines and neuro-hormonal disorders respectively [8].

Both serum sodium and arginine vasopressin (AVP) that involved in the regulation of body osmotic system, body water content, blood pressure and plasma volume, are highly disturb in Covid-19 and linked with poor clinical outcomes [9]. Therefore, this present study aimed to find the potential association between AVP serum level and inflammatory disorders in Covid-19.

2. Physiological profile of arginine vasopressin

AVP is a nonapeptide primarily synthesized by paraventricular (PVN) and supraoptic neurons of the hypothalamus that stored in the posterior hypothalamus. Expression of AVP gene induces release of pro-preAVP, which proteolysed to release AVP, neurophysin II and copeptin [10]. High plasma osmolarity during thirst and dehydration is regarded as the main determinant of AVP release; however stress nausea, vomiting, acidosis, fever, pro-inflammatory cytokines, sympathetic stimulation, hypovolemia and catecholamines also stimulate AVP release [11]. AVP is also considered as a neurotransmitter regulates activity of AVPergic neurons in response to the stimulating factors [12]. Neuronal aquaporin 4 receptor and transient receptor potential cation channel sense blood and cerebrospinal fluid osmolarity that control release of AVP [13]. Moreover, expression of hypothalamic AVP gene is regulated by gut microbiota since antibiotic therapy in mice decrease gut microbiota and expression of hypothalamic AVP gene [14]. Similarly, AVP affects growth of gut microbiota through modulation of gut inflammatory and stress response suggesting that gut microbiota may metabolize AVP [15]. It has been reported that AVP affects glucose metabolism, it stimulates glycogenolysis and glucagon release leading to hyperglycemia and metabolic disturbances [16].

AVP acts through G-protein coupled receptors V1 (V1A), V2, and V3 (V1B). V1A receptors are expressed in vascular smooth muscle, myocardium, hepatocytes, and platelets that involved in vasoconstrictions, platelet aggregation, myocardial hypertrophy, and glycogenolysis. V3 (V1B) receptors are expressed in the anterior pituitary responsible for release of prolactin, adrenocorticotrophic hormone (ACTH) and endorphin. V2 receptors are expressed in renal collecting duct, vascular smooth muscle, and vascular endothelium responsible for water reabsorption from kidney, vasodilation, and release of clotting factor VIII and von Willebrand factor [17,18]. Therefore, AVP leads to increase blood pressure directly through V1A-induced vasoconstriction or indirectly through activation of RAS, sympathetic flow and baroreflex sensitivity [19]. Despite of clinical significance of AVP, its measurement is limited due to short half-life, so instead copeptin, which is synthesized at the same time of AVP and correlated with plasma osmolarity, can be used as a prognostic factor due to long half-life. Therefore, copeptin is considered as a surrogate biomarker that reflects synthesis, level, and biological activity of AVP [20,21].

Thus, AVP controls blood pressure, plasma volume, kidney water reabsorption, and synthesis of clotting factors [Fig. 1].

It has been observed that AVP and copeptin are strongly increased in patients with septic shock that associated with systemic inflammatory disorders compared with infected patients without systemic inflammatory reactions [22]. Chassin et al. illustrated that administration of AVP V2 receptor agonist deamino-8-D-AVP reduces inflammatory changes in patients with pyelonephritis due to inhibition release of chemokines and NF-κB pathway, suggesting immune-regulatory effect of AVP [23]. However, AVP antagonist in patients with pulmonary tuberculosis restores the activity of protective immunity to counterbalance high AVP level in late active phase of disease [24]. In addition, beyond procalcitonin and C-reactive protein (CRP), AVP might be a promising biomarker in the diagnosis and poor prognosis of pneumonia [25]. Therefore, copeptin is regarded as a predictor biomarker for assessment severity and prognosis of acquired pneumonia [26]. Lopez et al. showed that high AVP in bacterial sepsis and pneumonia is associated with increased pulmonary microvascular permeability, thus AVP antagonist tolvaptan may reduce the severity in septic patients [27]. Similarly, copeptin serum level is correlated with severity of ventilator associated pneumonia [28]. These findings suggest that AVP plays a role in the pathophysiology of pneumonia and development of sepsis. However, elevation of AVP serum levels might be a compensatory mechanism to counteract pro-inflammatory cytokines-induced vasodilatory shock during sepsis.

On the other, dilution hyponatremia due to increasing AVP may impact the course of infection during sepsis. It has been illustrated that hyponatremia and elevated AVP are linked with poor clinical outcome and high mortality in patients with community acquired pneumonia [29].

Of note, hyponatremia is also associated with respiratory viral infections such as influenza virus (H1N1), parainfluenza virus, avian influenza (H7N9) and adenovirus [30]. In addition, hyponatremia is commonly connected to the human immune deficiency virus (HIV) infection mainly when associated with central nervous system (CNS).
and pulmonary co-infections due to development of syndrome of inappropriate antidiuretic hormone (SIADH) [31]. Hyponatremia is regarded as a predictor of immune dysfunction in HIV infection as it inversely correlated with CD4 T lymphocyte number and function [32].

Moreover, development of hyponatremia is also reported in other viral infections including Hantavirus, Ebola virus, and herpes simplex virus [33]. Indeed, CNS viral infections are associated with development of SIADH and hyponatremia in about 60% due to vomiting, dehydration, fever, acidosis and stress that activate release of AVP from hypothalamus [34]. Besides, drugs that are used in the management of secondary bacterial infections in patients with viral pneumonia like trimethoprim-sulfamethoxazole antibiotic may lead to hyponatremia in 60% of treated patients due to induction of natriuresis [35]. The underlying mechanism of SIADH and hyponatremia in respiratory viral infections might be neutrophilia and higher concentrations of pro-inflammatory cytokines that activate hypothalamus for release of AVP with subsequent hyponatremia [36]. Likewise, antiviral protease inhibitors ribavirin and paritaprevir therapy may lead to SIADH and hyponatremia [37].

3. Arginine vasopressin and Covid-19

It has been observed by different recent studies that physiological response due to fever, pain, hypovolemia, dehydration and psychological stress is characterized by activation release of AVP to counterbalance high blood viscosity in Covid-19 patients [38]. Abnormal activation of vasopressin system during SARS-CoV-2 infection is linked with poor clinical outcomes and prognosis in hospitalized Covid-19 patients with complications [9]. Tzoulis et al., longitudinal, retrospective cohort study confirmed that high AVP-induced hyponatremia is associated with poor prognosis due to high risk of respiratory failure in hospitalized Covid-19 patients [39]. In addition, hyponatremia without elevation of AVP is also linked with complications and mortality in Covid-19 patients [40], thus increasing AVP and/or hyponatremia are more correlated with Covid-19 severity. Besides, various case-report studies illustrated that SARS-CoV-2 infection is associated with development of SIADH due to progression of acute kidney injury-induced hyponatremia [41] or ALI-induced pulmonary vasconstriction [42] that together activate release of AVP by osmotic-independent pathway. The potential mechanisms for activation release of AVP in Covid-19 are stressful factors, hypoxic pulmonary vasconstriction, and reduction of left atrium filling due to dehydration and hypovolemia, and high pro-inflammatory cytokines [42].

Acute inflammatory response with a higher concentration of pro-inflammatory cytokines mainly IL-6 leads to significant stimulation of hypothalamic AVP with progression of hyponatremia. Besides, IL-6 inhibits attenuate systemic inflammation and development of SIADH suggesting that IL-6 is a prototypical pro-inflammatory cytokine, which activate release of hypothalamic AVP [43]. In Covid-19, IL-6 is highly activated and linked with development of cytokine storm and ALI/ARDS, and IL-6 blockade may mitigate systemic inflammatory reactions and ALI [44]. Therefore, IL-6 has dual effect in the stimulation of AVP release either directly as it cross blood brain barrier (BBB) and initiates activation of hyponatremus or indirectly through induction of ALI-induced pulmonary vasconstriction with reduction of cardiac atrial stretching [45]. As well, AVP stimulates release of IL-6 through activation of NF-kB pathway by V1a receptor leading to myocardial inflammation in the experimental heart failure [46]. Taken together, there is significant interaction between AVP and IL-6 during acute inflammatory reactions suggesting immunoregulatory effect of AVP on the innate immune response. Furthermore, low dose of AVP leads to immunomodulatory effect mainly in the lung through V2 receptor [47]. Both corticotrophin releasing hormone (CRH) and AVP are present in the immune cells and can be release in response to inflammation and stress. Also, AVP receptors are expressed on the immune cells that involved in antibody production and release of pro-inflammatory cytokines [48]. AVP also activates Th1 immune response leading to augmentation of mixed cellular immune response with further abnormal immune response [49].

Interestingly, abnormal immune response in Covid-19 that characterized by lymphopenia and abnormal T cell functions leading to cytokine storm and abnormal immune response-induced tissue injury [50]. Activated immune cells mainly T and B lymphocytes and released pro-inflammatory cytokines stimulate discharge of stored AVP from immune cells, which in a vicious cycle trigger release of pro-inflammatory cytokines [51]. Therefore, aberrant immune response in SARS-CoV-2 infection might be the potential cause for elevation of AVP [52].

Therefore, source of high AVP in Covid-19 is from hyponatremus and immune cells that together contribute into progression of inflammatory and immunological disorders in severe cases. In the recent researches, SARS-CoV-2 directly triggers macrophage and other immune cells through activation of NF-kB pathway for release of pro-inflammatory cytokines and progression of cytokine storm [53]. Besides, released AVP in Covid-19 may provoke inflammatory reactions through release of pro-inflammatory cytokines due to activation of NF-kB pathway [54]. Into the bargain, AVP-induced hyponatremia disturbs cellular osmolarity and activate NLRP3 inflammasome for secretion of IL-1β, which cross BBB and stimulate hypothalamus for secretion of AVP. In turn, AVP increases progression of hyponatremia with more activation of NLRP3 inflammasome/IL-1β axis and development of SIADH [55]. In addition, AVP and associated hyponatremia trigger NLRP3 inflammasome activation through IL-6 dependent pathway causing more propagation of inflammatory reactions in Covid-19 patients [56,57].

It has been observed that platelet activations, endothelial dysfunction and thrombosis in SARS-CoV-2 are due to activation of mitogen-activated protein kinase (MAPK) leading to pulmonary micro-vascular thrombosis and progression of ALI/ARDS [58]. Notably, AVP triggers MAPK-induced endothelial dysfunction with direct effect for release of clotting factors [59,60]. Remarkably, administration of AVP reduces development of ALI [61] however, Barcroft et al., illustrated in a case-report study that intramyometrial infiltration of AVP during laparoscopic myomyectomy leads to acute pulmonary edema and coronary vasospasm [62]. Thus, dose-dependent effect of AVP may affect the cardiopulmonary outcomes.

It has been shown that high mobility group box 1 (HMGB1) may lead to ALI in SARS-CoV-2 infection through activation of autophagy, which involved in the pathogenesis of SARS-CoV-2-induced ALI [63]. Yang et al. [64] illustrated that autophagy and endocytic pathway are involved in SARS-CoV-2 infections and linked with Covid-19 severity. As well, AVP induces autophagy pathway leading to progressive cell death and inflammation with activation of oxidative stress-induced release of HMGB1 [65,66]. Therefore, both SARS-CoV-2 infection and high AVP may augment autophagy-induced ALI.

On the other hand, SARS-CoV-2-induced downregulation of ACE2 with subsequent increase of AngII serum level since ACE2 metabolize AngII to vasodilator and protective Ang 1–7 [67]. High circulating AngII level provokes endothelial dysfunction, activation release of pro-inflammatory cytokines, thrombosis, and progression of ALI/ARDS [68]. Elevated AngII stimulates hypothalamicus to release of AVP, which causes hyponatremia and release of more inflammatory cytokines [69]. However, central administration of Ang1–7 inhibits release of AVP from hypothalamus via anti-inflammatory effect [70]. Furthermore, high AVP in SARS-CoV-2 infection might be due to AngII-induced hypothalamic activation or due to AngII-induced immune cells activation that also release AVP.

Of interest, the inhibitory GABAergic neurons inhibit pre-sympathetic hypothalamic PVN neurons. These GABAergic neurons have a higher expression of ACE2 receptors, thus down-regulation of these receptors during SARS-CoV-2 infection may suppress these inhibitory interneurons with activation of hypothalamic sympathetic neurons leading to sympathetic storm [71]. Excitingly, central
sympathetic stimulation due to SARS-CoV-2 infection increases circulating catecholamine, which activates macrophages and neutrophils for release of pro-inflammatory cytokines. Correspondingly, activated macrophages and neutrophils also release catecholamine, which act in a paracrine manner for augmentation release of pro-inflammatory cytokines [72]. Kim et al. illustrated that GABAergic neurons dysfunction activate release of AVP [73]. In addition, sympathetic storm trigger release of AVP release and vice versa via neuro-hormonal loop [74]. Thus, SARS-CoV-2 infection is associated with high AVP and sympathetic flow due to inhibition of central GABAergic neurons.

These findings give a clue that AVP action is augmented during SARS-CoV-2 infection and may participate for development of Covid-19 complications [Fig. 2].

4. Arginine vasopressin antagonists and Covid-19

Vasopressin receptor antagonists (VRAs) drugs that block AVP receptors used in the treatment of hyponatremia as in SIADH, heart failure and liver cirrhosis [75]. VRAs might be non-selective like conivaptan, which block V1 and V2 receptors, V1A receptor antagonist like relcosvaptan, V1B receptor antagonist like nelivaptan, and selective V2 receptor antagonist like tolvaptan [76]. VRAs may have potential role in

---

**Fig. 2.** The interaction between SARS-CoV-2 and Arginine vasopressin (AVP): SARS-CoV-2 through downregulation of ACE2, induction of acute kidney injury (AKI), acute lung injury (ALI), release of pro-inflammatory cytokines (PIC) and inhibition of GABAergic neurons stimulate hypothalamus for secretion of AVP. Released AVP activates NF-κB, NLRP3 inflammasome, release of PIC and induction of Autophagy leading to acute lung injury (ALI) acute respiratory distress syndrome (ARDS).
the management of hyponatremia in different viral infections including Covid-19 through block AVP effects, and silico study found that con-
vivaptan inhibits SARS-CoV-2 3C-like protease and viral RNA-dependent
polymerase [77]. Xiao et al., illustrated that VRAs may have anti-
hibiton SARS-CoV-2 effects [78]. Interestingly, tolvaptan has in vitro and
vivo antiviral effects against Zika virus [79].

On the other hand, tolvaptan has anti-inflammatory and anti-fibrotic

effects through inhibition of monocyte chemotactic protein-1(MCP-1) and

transforming growth factor β (TGF-β1) [80]. Both of MCP-1 and

TGF-β1 are involved in the inflammatory process during SARS-CoV-2

infection. Therefore, the antiviral and anti-inflammatory effects of VRAs may

inhibit AVP-induced hyponatremia and release of pro-inflammatory cytokines in Covid-19.

5. Conclusion

Release of AVP from hypothalamus is augmented in Covid-19 due to stress, high pro-inflammatory cytokines, high circulating AngII and in-
hibition of GABAergic neurons. In turn, high AVP level leads to induc-
tion of hyponatremia, inflammatory disorders, and development of complications in Covid-19 by activation of NF-

stress, high pro-inflammatory cytokines, high circulating AngII and in-
thelialisation of AVP-mediated inflammatory disorders and hyponatremia. Appreciation of these findings should trigger further research actions to confirm this association in a new perspective.

Ethics approval and consent to participate

Not applicable.

CRediT authorship contribution statement

Hayder M. Al-kuraishy: Conceptualization, Methodology, Validation, Resource, Writing – original draft, Supervision, Project administration. Ali I. Al-Gareeb: Conceptualization, Software. Safaa Qusti: Methodology, Software, Writing – original draft, Writing – review & editing. Eida M. Alshammari: Methodology, Writing – original draft, Writing – review & editing. Francis O. Atanu: Conceptualization, Methodology, Software, Writing – original draft, Writing – review & editing. Gaber El-Saber Batiha: Conceptualization, Validation, Re-
sources, Writing – original draft, Supervision, Project administration.

All authors have read and agreed to the published version of the manuscript.

Consent for publication

Not applicable.

Conflict of interest statement

The authors declare no conflict of interest.

References

[1] H.M. Al-kuraishy, M. Al-Naimi, C. Lungnier, A.I. Al-Gareeb, Macrolides and COVID-19: an optimum premise, Biomed. Biotechnol. Res. J. (2020) 3(1), 33.
[2] H. Al-Kuraishy, N. Hussien, M. Al-Naimi, A. Al-Buhadily, A. Al-Gareeb, C. Lungnier, Resin-angiotensin system and fibrinolytic pathway in COVID-19: one-way
[3] J. Danziger, M.L. Zeidel, Osmotic homeostasis, Clin. J. Am. Soc. Nephrol. CJASN 10 (2015) 852–862, https://doi.org/10.2215/CJN.07101315.
[4] N.G. Morgenthaler, J. Lee, J. Ouyang, R.D. Perrone, K. Stade, V.E. Torres, O. Devuyst, A.-O. Bankir, O. Melander, N. Bouby, Acute and chronic hyperglycemic effects of

methodology, from the precursor of vasopressin, Clin. Chem. 52 (1) (2006) 112–119.

vasopressin system during COVID-19 is associated with adverse clinical outcomes: what is old, what is new, and what is unknown? J. Clin. Endocrinol. Metab. 104 (11) (2019) 5406–5420.

P. Zhou, C. Ye, X. Ma, W.A.-O. Yin, T.I. Croll, Q. Zhou, X. He, X.A.-O. Zhang, D.A.-O. Yang, P. Wang, et al., Molecular basis of ligand recognition and activation of human V2 vasopressin receptor, Cell Res. 19 (2019) 1–3.

D. Kononen, H. Quasi, N.A.-O. Rossi, V1A, and V1B vasopressin receptors within the paracervical nuclear contribution to hypertensive in male rats exposed to chronic mild unpredictable stress, Integr. Comp. Physiol. 320 (3) (2021) R213–R225.

N.G. Morgensthaler, J. Struck, C. Fau- Alonso, C.Fau Alonso, A. Bergmann, A. Bergmann, Assy for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin, Clin. Chem. 52 (1) (2006) 112–119.

R.T. Gansevoort, M.D.A. van Gestel, A.B. Chapman, J.D. Ilais, F.S. Cerwicz, E. Higashihara, J. Lee, J. Ouyang, R.D. Perrone, K. Stade, V.E. Torres, O. Devuyst, I. TEMPO, Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease, Kidney Int. 96 (1) (2019) 159–169.

S. Ischbecher, J.Fau Dourler, G. Luckner, G.Fau Luckner, V.D. Mayr, V. Wenzel, H. Ulmer, N.G. Morgensthaler, W.H. Hashider, M.W. Dürner, H. Ulmer, The vasopressin and copeptin response to infection, severe sepsis, and septic shock, Crit. Care Med. 37 (2) (2009) 476–482.

C. Chasin, M.W. Horner, M. Bens, M. Lotz, J.-M. Goujon, S. Vimont, G. Arlet, A. Hertig, E. Rondeau, A. Quintanar-Stefano, R. Hernández-Pando, Involvement of vasopressin in the pathogenesis of pulmonary tuberculosis: a new therapeutic target? Front. Endocrinol. 10 (2019) 352.

M. Karakoulaki, D. Stolz, Biomarkers in pneumonia beyond procalcitonin, Int. J. Mol. Sci. 20 (8) (2019) 2004.

G.B. Mohamed, M.A. Saed, A.A. Abdelhalakeem, K. Salah, A.M. Saed, Predictive value of copeptin as a biomarker of community-acquired pneumonia, Electron. Physician 9 (2017) 4880–4885, https://doi.org/10.4103/2277-8288.84888.

E. Lopez, S. Fukuda, K. Modis, O. Fujiwara, B. Enkhtraivan, R. Trujillo-Abarca, K. Barra, F. Lima-Lopez, D. Perez-Bello, C. Szabo, D.S. Prough, P. Enckbaatar, Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis, Pharmacol. Res. 132 (2019) 105272, https://doi.org/10.1016/j.phrs.2020.105272.
[28] R. Seligman, N.G. Papasotiriou J Fau - Morghentaler, M. Morghenthaler Ng Fau - Meiner, P.J.J. Meiner Fau - Teixeira, P.J. Teixeira, Copepin, a novel prognostic biomarker in ventilator-associated pneumonia, Crit. Care. 12 (2008) 1-9.

[29] S. Krüger, S. Ewig, S. Gietersdorf, O. Hartmann, D. Frechen, G. Rohde, N. Suttrop, T. Weile, Dystrophia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia, Gen. Hospital. Care. 1 (2004) 117-16.

[30] D.B. Oliveira, A.C.L. Durigon El Fau - Carvalho, A.L. Carvalho Ac Fau - Leal, T.S. Leal Fau - Souza, L.M. Souza Ts Fau - Tomazelli, C.T.P. Tomazelli Lm Fau - Morais, S.E. Morais Cn Fau - Vieira, A.E. Vieira Se Fau - Giliço, K.E. Giliço El Fau - Stewien, K.E. Stewien, Epidemiology and genetic variability of human metameasivirus during a 4-year-long study in Southeastern Brazil, J. Med. Virol. 82 (2010) 1103-1109.

[31] Z. Shu, Z. Tian, J. Chen, J. Ma, A. Abudureyimu, Q. Qian, L. Zhuo, HIV/AIDS-related hyponatremia: an old but still serious problem, Ren. Fail. 40 (2018) 68-74, https://doi.org/10.1080/0886022X.2017.1419975.

[32] A.L. Królka, A. Kruczkowska, M. Krajewska, M.A. Kusztal, Hyponatremia in infectious diseases-a literature review, Int. J. Environ. Res. Public. Health 17 (2020) 5320, https://doi.org/10.3390/ijerph17155320.

[33] E.M. Gromgiu, B. Karabuga, E. Gemcioglu, B. Karabuga, A. Ercan, A. Erden, A case of inappropriate antidiuretic hormone secretion syndrome associated with COVID-19 pneumonia, Acta Clin. Exp. 21 (2020) 00859.

[34] Cl. Easaw, J.C. Easaw, Evaluation of Z. Shu, Z. Tian, J. Chen, J. Ma, A. Abudureyimu, Q. Qian, L. Zhuo, HIV/AIDS-related hyponatremia: an old but still serious problem, Ren. Fail. 40 (2018) 68-74, https://doi.org/10.1080/0886022X.2017.1419975.

[35] A.L. Królka, A. Kruczkowska, M. Krajewska, M.A. Kusztal, Hyponatremia in infectious diseases-a literature review, Int. J. Environ. Res. Public. Health 17 (2020) 5320, https://doi.org/10.3390/ijerph17155320.

[36] T.E. West, A. von Saint Andr, E. Gemcioglu, B. Karabuga, A. Ercan, A. Erden, A case of inappropriate antidiuretic hormone secretion syndrome associated with COVID-19 pneumonia, Acta Clin. Exp. 21 (2020) 00859.

[37] J.H. Kim, J.H. Park, M. Eisenhut, J.W. Yu, J.I. Shin, Inflammasome activation by K. Yamagata, N. Sone, S. Suguyama, T. Nabika, Different effects of arginine vasopressin-stimulated facilitated urea permeability in rat terminal IMCDs, Am. J. Physiol. Ren. Physiol. 279 (2000) F840-841, https://doi.org/10.1152/ajprenal.2000.279.5.F840, https://doi.org/10.1152/ajprenal.2000.279.5.F840.

[38] B. Friedman, J. Cirulli, Hyponatremia in critical care patients: frequency, outcome, and management, Am. J. Kidney Dis. 16 (2000) 110-111, https://doi.org/10.1053/ajkd.2000.30524.

[39] J.K. Hodax, S.R. Biało, A. Yalcindag, SIADH in systemic JIA resolving after treatment with anakinra, Pediatrics 141 (2018) 1447, https://doi.org/10.1542/peds.2016-2462.

[40] B. Liu, M. Li, Z. Zhou, X. Guan, Y. Xiang, Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J. Autoimmun. 111 (2020), 102452, https://doi.org/10.1016/j.jaut.2020.102452.

[41] A. Quintanar-Stephano, V. Viuela-Berni, N. Macías-Segura, F. Valdez-Urias, K. Jaut.2020.102452.

[42] M. Bentoumi-Loaec, N. Benaouicha, E. Canet, G. Chapelet, et al., Hyponatremia is associated with cytokine storm and is a potential therapeutic target, Life Sci. 257 (2020), 118114.

[43] S. Gabbri, M.A. Nazari, D. Taieb, J. Klubo-Gwizdzienka, K. Parak, Catecholamine physiology and its implications in patients with COVID-19, Lancet Diabetes Endocrinol. 8 (2020) 978-986, https://doi.org/10.1016/S2213-8587(20)30042-0.

[44] Y. Wang, B. Chen, Y. Li, L. Zhang, Y. Wang, X. Xiao, Q.A.-O. Qin, The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis, J. Med. Virol. 93 (2021) 1370-1377.

[45] D. Darif, I. Hammi, A. Kihel, I. El Idrissi Saik, F. Guessous, K. Akarid, The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb. Pathog. 153 (2021), 105277, https://doi.org/10.1016/j.micpath.2020.105277.

[46] K. Yamagata, N. Sone, S. Suguyama, T. Nabika, Different effects of arginine vasopressin on high-mobility group box 1 expression in astrocytes isolated from stroke-prone spontaneously hypertensive rats and congenic SHRsp1_18 rats, Int. J. Exp. Pathol. 97 (2) (2016) 97-106.

[47] Y. Wang, B. Chen, Y. Li, L. Zhang, Y. Wang, X. Xiao, Q.A.-O. Qin, The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis, J. Med. Virol. 93 (2021) 1370-1377.

[48] S. Gabbri, M.A. Nazari, D. Taieb, J. Klubo-Gwizdzienka, K. Parak, Catecholamine physiology and its implications in patients with COVID-19, Lancet Diabetes Endocrinol. 8 (2020) 978-986, https://doi.org/10.1016/S2213-8587(20)30042-0.

[49] B. Friedman, J. Cirulli, Hyponatremia in critical care patients: frequency, outcome, and management, Am. J. Kidney Dis. 16 (2000) 110-111, https://doi.org/10.1053/ajkd.2000.30524.

[50] J.H. Kim, J.H. Park, M. Eisenhut, J.W. Yu, J.I. Shin, Inflammasome activation by K. Yamagata, N. Sone, S. Suguyama, T. Nabika, Different effects of arginine vasopressin-stimulated facilitated urea permeability in rat terminal IMCDs, Am. J. Physiol. Ren. Physiol. 279 (2000) F840-841, https://doi.org/10.1152/ajprenal.2000.279.5.F840, https://doi.org/10.1152/ajprenal.2000.279.5.F840.
X. Xiao, C. Wang, D. Chang, Y. Wang, X. Dong, T. Jiao, Z. Zhao, L. Ren, C.S. Dela Cruz, L. Sharma, et al., Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2, Front. Immunol. (2020) 11.

X. Chen, R.-H. Luo, Z. Yao, C. Zheng, Q. Tang, W.-Y. Pang, F. Wang, L. Yang, S. Xiong, Z. Yongtang, Tolvaptan, an FDA-approved drug, inhibits zika virus infection both in vitro and in vivo, J. Chin. Pharm. Sci. 30 (2021) 218–229.

Yamazaki Takanori, Izumi Yasukatsu, Nakamura Yasuhiro, Yamaguchi Takehiro, Hanatani Akihisa, Shimada Kenei, Iwao Hiroshi, Yoshiyama Minoru, Correction (doi:doi:), Circulation 131 (2015) 535, https://doi.org/10.1161/circ.126.suppl_21. A9412.